Recent Publications
David Azoulay: Prediction of Chemotherapy-Induced Peripheral Neuropathy in Patients with Lymphoma and Myeloma: the Roles of Brain-Derived Neurotropic Factor Protein Levels and A Gene Polymorphism (J Clin Neurol)
Brain-derived neurotrophic factor (BDNF) is a neuronal growth factor that plays an essential role in the maintenance of the nervous system. We have evaluated the peripheral blood protein levels of BDNF and the valine-to-methionine substitution at codon 66 (Val66Met) single-nucleotide polymorphism (SNP) as potential biomarkers for the early recognition of chemotherapy-induced peripheral neuropathy (CIPN) in non-Hodgkin lymphoma and multiple myeloma patients.
David Azoulay: Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine‐induced peripheral neuropathy in patients with lymphoma (BJH)
Vincristine is a chemotherapeutic agent that is associated with chemotherapy‐induced peripheral neuropathy (CIPN) (Legha, 1986), although the reason why some patients are more vulnerable to CIPN than others remains unclear. Our preliminary studies, showing a possible link between CIPN and blood levels of brain‐derived neurotrophic factor (BDNF) (Azoulay et al, 2014), point to BDNF as a potential biomarker for CIPN. The current study explored the effects of serum BDNF and the BDNF‐Val66Met, a single nucleotide polymorphism (SNP) causing deficit in cellular distribution and secretion of BDNF in the neuronal cells (Egan et al, 2003) of patients with non‐Hodgkin lymphoma (NHL) who develop CIPN.
